Gerresheimer AG (GRRMF) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören Gerresheimer AG (GRRMF), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 43/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 16 Mar 2026Gerresheimer AG (GRRMF) Sağlık ve Boru Hattı Genel Bakışı
Gerresheimer AG manufactures specialized packaging solutions and drug delivery systems for the healthcare industry, focusing on plastics, glass, and advanced technologies. With a global presence and a history dating back to 1864, the company serves pharmaceutical, biotech, and cosmetic sectors with a diverse product portfolio.
Yatırım Tezi
Gerresheimer AG presents an investment opportunity within the healthcare sector, driven by its diverse product portfolio and global presence. The company's focus on drug delivery systems and specialized packaging caters to the growing demand for advanced healthcare solutions. With a market capitalization of $0.75 billion and a P/E ratio of 26.14, Gerresheimer exhibits a moderate valuation. Key growth catalysts include the expansion of its Advanced Technologies division and increasing demand for injectable drugs. However, investors may want to evaluate the company's relatively low profit margin of 1.0% and potential risks associated with regulatory changes and competition. The dividend yield is 0.23%.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Market capitalization of $0.75 billion indicates a mid-sized player in the medical instruments and supplies market.
- P/E ratio of 26.14 suggests a moderate valuation compared to its earnings.
- Profit margin of 1.0% reflects a need for improved operational efficiency.
- Gross margin of 26.9% indicates the profitability of its products before operating expenses.
- Dividend yield of 0.23% provides a modest income stream for investors.
Rakipler & Benzerleri
Güçlü Yönler
- Global presence and established reputation in the healthcare industry.
- Diverse product portfolio spanning packaging, drug delivery systems, and advanced technologies.
- Long-standing relationships with major pharmaceutical companies.
- Expertise in regulatory compliance and quality control.
Zayıflıklar
- Relatively low profit margin compared to industry peers.
- Dependence on the pharmaceutical industry, making it susceptible to regulatory changes.
- Limited brand recognition among consumers.
- Exposure to currency fluctuations due to its global operations.
Katalizörler
- Ongoing: Expansion of the Advanced Technologies division with new product launches in micro pumps and smart drug delivery systems.
- Ongoing: Increasing demand for injectable drugs driving growth in the Plastics & Devices division.
- Ongoing: Strategic partnerships and acquisitions to expand product portfolio and market reach.
- Upcoming: Potential regulatory approvals for new drug delivery devices in key markets.
- Ongoing: Focus on sustainable packaging solutions attracting environmentally conscious customers.
Riskler
- Potential: Intense competition from established players and new entrants in the healthcare packaging market.
- Potential: Stringent regulatory requirements and potential product recalls affecting product sales and reputation.
- Potential: Economic downturns affecting healthcare spending and demand for pharmaceutical products.
- Ongoing: Exposure to currency fluctuations due to its global operations.
- Ongoing: Relatively low profit margin compared to industry peers, requiring improved operational efficiency.
Büyüme Fırsatları
- Expansion of Advanced Technologies Division: Gerresheimer's Advanced Technologies division, which develops smart drug delivery systems like micro pumps, represents a significant growth opportunity. The market for advanced drug delivery systems is projected to reach $24.7 billion by 2027, driven by the increasing demand for personalized medicine and self-administration options. By focusing on innovative solutions for chronic diseases like Parkinson's and heart failure, Gerresheimer can capture a larger share of this expanding market. Timeline: Ongoing.
- Increasing Demand for Injectable Drugs: The rising prevalence of chronic diseases and the growing biologics market are driving increased demand for injectable drugs, creating a significant opportunity for Gerresheimer's Plastics & Devices division. The global injectable drug market is expected to reach $790.7 billion by 2030. Gerresheimer's expertise in manufacturing prefillable syringes and other injectable drug delivery systems positions it well to capitalize on this trend. Timeline: Ongoing.
- Growth in Emerging Markets: Emerging markets, with their rapidly growing populations and increasing healthcare expenditure, present a substantial growth opportunity for Gerresheimer. These markets are experiencing a rising demand for pharmaceutical packaging and drug delivery systems. By expanding its presence in regions like Asia-Pacific and Latin America, Gerresheimer can tap into new revenue streams and diversify its geographic footprint. Timeline: Ongoing.
- Strategic Partnerships and Acquisitions: Gerresheimer can pursue strategic partnerships and acquisitions to expand its product portfolio, enhance its technological capabilities, and strengthen its market position. Collaborating with pharmaceutical companies and biotech firms can facilitate the development of innovative drug delivery solutions and secure long-term supply contracts. Acquisitions of complementary businesses can provide access to new markets and technologies. Timeline: Ongoing.
- Focus on Sustainable Packaging Solutions: With increasing environmental awareness, there is a growing demand for sustainable packaging solutions in the healthcare industry. Gerresheimer can capitalize on this trend by developing and offering eco-friendly packaging options, such as recyclable plastics and bio-based materials. By positioning itself as a leader in sustainable packaging, Gerresheimer can attract environmentally conscious customers and gain a competitive advantage. Timeline: Ongoing.
Fırsatlar
- Expanding into emerging markets with growing healthcare expenditure.
- Developing innovative drug delivery systems for chronic diseases.
- Acquiring complementary businesses to expand its product portfolio.
- Capitalizing on the increasing demand for sustainable packaging solutions.
Tehditler
- Intense competition from established players and new entrants.
- Stringent regulatory requirements and potential product recalls.
- Economic downturns affecting healthcare spending.
- Disruptive technologies that could render existing products obsolete.
Rekabet Avantajları
- Specialized Expertise: Gerresheimer's deep expertise in manufacturing specialized packaging and drug delivery systems creates a barrier to entry for new competitors.
- Long-Term Relationships: The company's long-standing relationships with pharmaceutical companies and biotech firms provide a stable revenue stream and a competitive advantage.
- Regulatory Compliance: Gerresheimer's adherence to stringent regulatory requirements in the healthcare industry ensures product quality and safety, building trust with customers.
- Global Footprint: The company's global manufacturing and distribution network allows it to serve customers in both established and emerging markets.
GRRMF Hakkında
Founded in 1864 and headquartered in Düsseldorf, Germany, Gerresheimer AG has evolved into a leading global manufacturer of packaging products and drug delivery devices. The company operates through three primary divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The Plastics & Devices division offers a range of drug delivery systems, including inhalers, insulin pen systems, and prefillable syringes, along with diagnostic systems for the pharma, biotech, diagnostics, and medical technology industries. This division also provides containers and closures, PET bottles, eye droppers, nasal sprays, nebulizers, applicators, and accessories for solid, liquid, and ophthalmic applications, as well as bottles and containers for nutritional supplements. The Primary Packaging Glass division focuses on glass primary packaging for the pharma and cosmetics industries, producing infusion, dropper, and syrup bottles, injection vials, ampoules, and cartridges. Additionally, it offers miniature bottles and glass containers for liquid food, spices, and spirits, along with packaging solutions for fragrances, deodorants, skin care, and wellness products, as well as beauty and pharmaceutical products. The Advanced Technologies division is dedicated to developing smart drug delivery systems, such as micro pumps, which are used to self-administer medication for conditions like Parkinson's disease or heart failure. Gerresheimer serves a diverse customer base across the pharmaceutical, biotech, diagnostics, medical technology, and cosmetics industries, with a global footprint that allows it to cater to both established and emerging markets.
Ne Yaparlar
- Manufactures plastic containers and closures for liquid and solid pharmaceuticals.
- Produces glass vials, ampoules, and cartridges for injectable drugs.
- Develops and manufactures drug delivery systems, including inhalers and pen systems.
- Offers packaging solutions for the cosmetics and personal care industries.
- Creates advanced micro pumps for self-administration of medication.
- Provides diagnostic systems for the pharma and biotech sectors.
İş Modeli
- Manufacturing and selling primary packaging glass for pharmaceutical and cosmetic products.
- Producing plastic containers and drug delivery systems for the healthcare industry.
- Developing and commercializing advanced drug delivery technologies.
- Generating revenue through long-term supply contracts with pharmaceutical companies.
Sektör Bağlamı
Gerresheimer AG operates in the medical instruments and supplies industry, which is characterized by continuous innovation and stringent regulatory requirements. The market is driven by increasing healthcare expenditure, an aging population, and the rising prevalence of chronic diseases. The competitive landscape includes companies like BOEUF, EBOSY, EKTAF, EKTAY, and GENSF, each vying for market share through product differentiation and strategic partnerships. Trends such as personalized medicine and the growing demand for self-administered drug delivery systems are shaping the industry's future.
Kilit Müşteriler
- Pharmaceutical companies requiring primary packaging for drugs.
- Biotech firms needing drug delivery systems for injectable medications.
- Cosmetics companies seeking packaging solutions for beauty products.
- Healthcare providers using diagnostic systems and drug delivery devices.
Finansallar
Grafik & Bilgi
Gerresheimer AG (GRRMF) hisse senedi fiyatı: Price data unavailable
Son Haberler
GRRMF için son haber bulunmamaktadır.
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
GRRMF için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
GRRMF için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, GRRMF'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Rakipler & Benzerleri
Yönetim: Uwe Ferdinand Röehrhoff
CEO
Uwe Ferdinand Röehrhoff has served as the CEO of Gerresheimer AG, managing a workforce of 13,632 employees. His background includes extensive experience in the pharmaceutical and healthcare industries. He has held various leadership positions in multinational corporations, focusing on strategic planning, operational excellence, and business development. Röehrhoff's expertise spans across multiple functional areas, including manufacturing, supply chain management, and sales and marketing. His academic credentials include advanced degrees in engineering and business administration.
Sicil: Under Uwe Ferdinand Röehrhoff's leadership, Gerresheimer AG has focused on expanding its global footprint and strengthening its position as a leading provider of packaging solutions and drug delivery systems. Key achievements include the successful integration of strategic acquisitions, the implementation of operational efficiency initiatives, and the development of innovative products for the healthcare industry. The company has also made significant investments in research and development to drive future growth.
GRRMF OTC Piyasa Bilgileri
The OTC Other tier, where Gerresheimer AG (GRRMF) trades, represents the lowest tier of the over-the-counter (OTC) market. Unlike stocks listed on major exchanges like the NYSE or NASDAQ, companies on the OTC Other tier often have limited reporting requirements and may not meet the minimum financial standards required for exchange listing. This tier typically includes companies with limited operating history, penny stocks, and those facing financial distress. Investing in OTC Other stocks carries significantly higher risks compared to exchange-listed securities due to the lack of regulatory oversight and transparency.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited Disclosure: The lack of comprehensive and readily available financial information increases the risk of investing in GRRMF.
- Low Liquidity: Limited trading volume can make it difficult to buy or sell shares without affecting the price.
- Price Volatility: OTC stocks are often subject to greater price swings due to lower trading volumes and potential for manipulation.
- Regulatory Scrutiny: OTC-listed companies may face increased regulatory scrutiny and potential delisting.
- Information Asymmetry: The limited availability of information can create an uneven playing field for investors.
- Verify the company's financial statements through independent sources.
- Assess the company's management team and their track record.
- Research the company's industry and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Evaluate the company's corporate governance practices.
- Monitor news and regulatory filings related to the company.
- Consult with a financial advisor before making any investment decisions.
- Established Operations: Gerresheimer AG has a long operating history dating back to 1864, suggesting a degree of stability and experience.
- Global Presence: The company's global manufacturing and distribution network indicates a significant scale of operations.
- Industry Recognition: Gerresheimer AG is a recognized player in the healthcare packaging and drug delivery systems market.
- Customer Base: The company serves major pharmaceutical companies and biotech firms, indicating a level of trust and credibility.
- Management Team: The presence of an experienced CEO, Uwe Ferdinand Röehrhoff, suggests capable leadership.
GRRMF Healthcare Hisse Senedi SSS
GRRMF için değerlendirilmesi gereken temel faktörler nelerdir?
Gerresheimer AG (GRRMF) şu anda yapay zeka skoru 43/100, düşük puanı gösteriyor. Temel güçlü yan: Global presence and established reputation in the healthcare industry.. İzlenmesi gereken birincil risk: Potential: Intense competition from established players and new entrants in the healthcare packaging market.. Bu bir finansal tavsiye değildir.
GRRMF MoonshotScore'u nedir?
GRRMF şu anda MoonshotScore'da 43/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
GRRMF verileri ne sıklıkla güncellenir?
GRRMF fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler GRRMF hakkında ne diyor?
GRRMF için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
GRRMF'a yatırım yapmanın riskleri nelerdir?
GRRMF için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Intense competition from established players and new entrants in the healthcare packaging market.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
GRRMF'ın P/E oranı nedir?
GRRMF için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için GRRMF'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
GRRMF aşırı değerli mi, yoksa düşük değerli mi?
Gerresheimer AG (GRRMF)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
GRRMF'ın temettü verimi nedir?
Gerresheimer AG (GRRMF) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Financial data may be delayed or incomplete due to OTC listing.
- AI analysis pending for GRRMF.